Rheumatoid arthritis, abbreviated as RA, is a type of autoimmune disease that leads to inflammation and stiffness of the joints. If neglected, it results in deformity of the joint, pain and loss of functional ability. Adalimumab is a TNF inhibitor brand-named Humira, specifically used in patients with moderate to severe rheumatoid arthritis when other drugs have provided inadequate relief. TNF and inflammation How the drug works The drug belongs to a general class of drugs referred to as biological agents or biologics, and it works by preventing the action of a protein referred to as TNF, which provokes inflammation.

Are you looking for Adalimumab injection? Adalimumab is a self-administered drug that is given through subcutaneous injections and the dosage administered is usually once in one or two weeks. In their case, it usually takes several weeks to observe the RA symptoms start improving. Some of them include reactions at the site of injection, increasing susceptibility to infections, and, in a very limited number of patients, some nervous disorders and specific types of cancer. Nevertheless, research has shown that adalimumab can effectively treat RA by inducing remission and preventing further joint deterioration if administered according to the prescription of a healthcare provider.

Regarding antibiotics, the world is facing one of the major health risks in the form of resistance. Most of the ordinary bacteria have developed a resistance to more than one type of antibiotics, as such, infections have become more difficult to handle. Among all the resistant bacterium, one is Acinetobacter baumannii, which leads to pneumonia, bloodstream infection, and surgical site infection in healthcare associated settings.

Acinetobacter is one of the most problematic highly resistant bacteria which has few treatment options, and colistin is one of the older antibiotics that are now considered as the last resort. It is given through an injection and is more toxic than the current antibiotics on the market and has been known to cause effects such as kidney damage and neuropathy. However, some studies have reported that intravenous Colistin injection can serve as the last resort for treating extremely antibiotic-resistant organisms.

The implications of safety and efficacy, the need to adhere to antibiotic stewardship, and the fact that antibiotics are developed at a slow pace also poses challenges to clinicians. This is true despite the fact that medications such as adalimumab, a biological agent, have significantly transformed the management of autoimmune diseases if appropriately applied.